Positive News SentimentPositive NewsNASDAQ:ORMP Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis $2.20 -0.01 (-0.45%) Closing price 04:00 PM EasternExtended Trading$2.19 -0.01 (-0.45%) As of 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Oramed Pharmaceuticals Stock (NASDAQ:ORMP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oramed Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.17▼$2.2150-Day Range$2.06▼$2.3052-Week Range$1.82▼$3.09Volume78,754 shsAverage Volume138,985 shsMarket Capitalization$90.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York. Read More Oramed Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreORMP MarketRank™: Oramed Pharmaceuticals scored higher than 20% of companies evaluated by MarketBeat, and ranked 873rd out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Oramed Pharmaceuticals.Read more about Oramed Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Oramed Pharmaceuticals are expected to decrease in the coming year, from ($0.03) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oramed Pharmaceuticals is -6.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oramed Pharmaceuticals is -6.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOramed Pharmaceuticals has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Oramed Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.20% of the float of Oramed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverOramed Pharmaceuticals has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Oramed Pharmaceuticals has recently decreased by 0.12%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOramed Pharmaceuticals does not currently pay a dividend.Dividend GrowthOramed Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.20% of the float of Oramed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverOramed Pharmaceuticals has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Oramed Pharmaceuticals has recently decreased by 0.12%, indicating that investor sentiment is improving. News and Social Media3.7 / 5News Sentiment1.59 News SentimentOramed Pharmaceuticals has a news sentiment score of 1.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Oramed Pharmaceuticals this week, compared to 1 article on an average week.Search Interest9 people have searched for ORMP on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oramed Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders17.80% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.73% of the stock of Oramed Pharmaceuticals is held by institutions.Read more about Oramed Pharmaceuticals' insider trading history. Receive ORMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ORMP Stock News HeadlinesOramed Pharm Approves Stock Incentive Plan AmendmentAugust 21, 2025 | tipranks.comWith Substantial Liquidity, ORMP Has Generated Gains & Income From Investment PortfolioJuly 29, 2025 | msn.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.August 28 at 2:00 AM | American Alternative (Ad)ORMP - Oramed Pharmaceuticals Inc Trailing Returns - MorningstarJuly 2, 2025 | morningstar.comMOramed Pharmaceuticals Inc. (ORMP) - Yahoo FinanceJuly 2, 2025 | ca.finance.yahoo.comORMP - Oramed Pharmaceuticals Inc Executives - MorningstarJune 27, 2025 | morningstar.comMWe're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn RateJune 27, 2025 | finance.yahoo.comOramed Pharm Extends Stock Buyback ProgramMay 21, 2025 | tipranks.comSee More Headlines ORMP Stock Analysis - Frequently Asked Questions How have ORMP shares performed this year? Oramed Pharmaceuticals' stock was trading at $2.42 on January 1st, 2025. Since then, ORMP stock has decreased by 9.1% and is now trading at $2.20. How were Oramed Pharmaceuticals' earnings last quarter? Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) released its earnings results on Thursday, August, 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.01. Who are Oramed Pharmaceuticals' major shareholders? Oramed Pharmaceuticals' top institutional investors include BML Capital Management LLC (7.55%), Bank of America Corp DE (0.35%), Peapod Lane Capital LLC (0.21%) and Connor Clark & Lunn Investment Management Ltd. (0.15%). Insiders that own company stock include Michael Rabinowitz and Nadav Kidron. View institutional ownership trends. How do I buy shares of Oramed Pharmaceuticals? Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oramed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oramed Pharmaceuticals investors own include TransEnterix (TRXDW), Compugen (CGEN), Sarepta Therapeutics (SRPT), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD) and Gilead Sciences (GILD). Company Calendar Last Earnings8/14/2025Today8/28/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ORMP CIK1176309 Webwww.oramed.com Phone(844) 967-2633Fax972-2566-0004Employees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.06 million Net MarginsN/A Pretax Margin-1,110.80% Return on Equity-19.37% Return on Assets-18.28% Debt Debt-to-Equity RatioN/A Current Ratio26.82 Quick Ratio26.81 Sales & Book Value Annual Sales$1.34 million Price / Sales66.55 Cash FlowN/A Price / Cash FlowN/A Book Value$3.75 per share Price / Book0.58Miscellaneous Outstanding Shares41,000,000Free Float33,705,000Market Cap$89.18 million OptionableOptionable Beta1.60 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ORMP) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.